In-hospital mortality and thrombotic complications in patients treated with prothrombin complex concentrate for a factor Xa inhibitor–associated major bleeding event
| Reference . | Overall in-hospital mortality, n . | Overall in-hospital cumulative mortality, % . | Overall in-hospital mortality rate (per 100 person-days) . | In-hospital thrombotic events, n . | In-hospital thrombotic events cumulative incidence, % . | In-hospital thrombotic event rate (per 100 person-days) . | Hemostatic adequacy*, n (%) . |
|---|---|---|---|---|---|---|---|
| Allison7 | 5 | 15% | 2.5 | 0 | 0 | 0 | 26 (84%) |
| Berger9 | 4 | 18% | 3.8 | 2 | 9% | 1.9 | 17 (94%) |
| Dybdahl10 | 8 | 23% | 4.0 | 1 | 3% | 0.5 | N/A |
| Grandhi11 | 6 | 33% | 4.8 | 1 | 6% | 0.8 | 17 (94%) |
| Harrison12 | 2 | 14% | 2.2 | 0 | 0 | 0 | 13 (93%) |
| Müller13 | 7 | 9% | 2.0 | N/A | N/A | N/A | N/A |
| Sheikh-Taha14 | 6 | 21% | 3.9 | 1 | 3% | 0.7 | 21 (72%) |
| Smith15 | 5 | 16% | 2.4 | 0 | 0 | 0 | 25 (81%) |
| Testa6 | 5 | 23% | 8.5 | N/A | N/A | N/A | N/A |
| Reference . | Overall in-hospital mortality, n . | Overall in-hospital cumulative mortality, % . | Overall in-hospital mortality rate (per 100 person-days) . | In-hospital thrombotic events, n . | In-hospital thrombotic events cumulative incidence, % . | In-hospital thrombotic event rate (per 100 person-days) . | Hemostatic adequacy*, n (%) . |
|---|---|---|---|---|---|---|---|
| Allison7 | 5 | 15% | 2.5 | 0 | 0 | 0 | 26 (84%) |
| Berger9 | 4 | 18% | 3.8 | 2 | 9% | 1.9 | 17 (94%) |
| Dybdahl10 | 8 | 23% | 4.0 | 1 | 3% | 0.5 | N/A |
| Grandhi11 | 6 | 33% | 4.8 | 1 | 6% | 0.8 | 17 (94%) |
| Harrison12 | 2 | 14% | 2.2 | 0 | 0 | 0 | 13 (93%) |
| Müller13 | 7 | 9% | 2.0 | N/A | N/A | N/A | N/A |
| Sheikh-Taha14 | 6 | 21% | 3.9 | 1 | 3% | 0.7 | 21 (72%) |
| Smith15 | 5 | 16% | 2.4 | 0 | 0 | 0 | 25 (81%) |
| Testa6 | 5 | 23% | 8.5 | N/A | N/A | N/A | N/A |
N/A, not available.
Based on evaluable patients, which may be a smaller sample than the total sample.